Sagittarius Life Science Corp Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, sales was TWD 268.86 million compared to TWD 301.2 million a year ago. Net loss was TWD 45.16 million compared to TWD 40.47 million a year ago. Basic loss per share from continuing operations was TWD 1.39 compared to TWD 1.24 a year ago. Diluted loss per share from continuing operations was TWD 1.39 compared to TWD 1.24 a year ago.